239 related articles for article (PubMed ID: 23130019)
1. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.
Roco A; Quiñones L; Agúndez JA; García-Martín E; Squicciarini V; Miranda C; Garay J; Farfán N; Saavedra I; Cáceres D; Ibarra C; Varela N
Front Genet; 2012; 3():229. PubMed ID: 23130019
[TBL] [Abstract][Full Text] [Related]
2. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
4. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.
Chowbay B; Zhou S; Lee EJ
Drug Metab Rev; 2005; 37(2):327-78. PubMed ID: 15931768
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW; Tshering G; Na-Bangchang K
J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
9. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
10. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N; Ghasim H; Rouini M; Daali Y; Ardakani YH
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442448
[TBL] [Abstract][Full Text] [Related]
12. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile.
Muñoz S; Vollrath V; Vallejos MP; Miquel JF; Covarrubias C; Raddatz A; Chianale J
Pharmacogenetics; 1998 Aug; 8(4):343-51. PubMed ID: 9731721
[TBL] [Abstract][Full Text] [Related]
14. Genotype frequencies of polymorphic GSTM1, GSTT1, and cytochrome P450 CYP1A1 in Mexicans.
Montero R; Araujo A; Carranza P; Mejía-Loza V; Serrano L; Albores A; Salinas JE; Camacho-Carranza R
Hum Biol; 2007 Jun; 79(3):299-312. PubMed ID: 18078203
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
16. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people.
Quiñones L; Lucas D; Godoy J; Cáceres D; Berthou F; Varela N; Lee K; Acevedo C; Martínez L; Aguilera AM; Gil L
Cancer Lett; 2001 Dec; 174(1):35-44. PubMed ID: 11675150
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2009 Dec; 10():124. PubMed ID: 19954515
[TBL] [Abstract][Full Text] [Related]
19. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.
Kurose K; Sugiyama E; Saito Y
Drug Metab Pharmacokinet; 2012; 27(1):9-54. PubMed ID: 22123129
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation of cytochrome P450 in Uyghur Chinese population.
Qi G; Li D; Zhang X
Drug Metab Pharmacokinet; 2018 Feb; 33(1):55-60. PubMed ID: 29233455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
